歌礼制药：选定激动剂多肽ASC35进入临床开发阶段

Core Viewpoint - The company, Gilead Sciences, has selected ASC35 as a clinical development candidate, which is expected to be a best-in-class monthly subcutaneous injection GLP-1R/GIPR dual agonist for treating obesity and related metabolic diseases [1] Group 1 - Gilead plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for ASC35 [1] - ASC35 is being developed as both a monotherapy and in combination therapy for treating cardiovascular metabolic diseases, including obesity, diabetes, and metabolic dysfunction-associated steatotic liver disease (MASH) [1]